Introduction
Recently, dramatic declines in human immunodeficiency virus (HIV)-associated morbidity and mortality have been achieved as a result of highly active antiretroviral combination therapies, including protease inhibitors and reverse transcriptase inhibitors.
1,2 However, treatment failure occurs at a rate as high as 20-50%, 2 and combination therapy will not be sufficient for its eradication. 3 As drugs susceptible to multidrug-resistant HIV are not yet available, the development of a new generation of therapies remains a major priority. Among new treatment strategies, preventing the virus from entering a cell would be an attractive option for new antiviral agents. [4] [5] [6] [7] [8] [9] [10] [11] We have demonstrated previously that transplantation of env-associated gene transduced bone marrow cells protected mice from ecotropic retrovirus-induced disease. 12 This env gene, the a truncated endogenous retrovirus which expresses the env glycoprotein and strongly restricts infection by the ecotropic murine leukemia virus (MuLV) in wild mice, probably through receptor interference. [13] [14] [15] [16] [17] [18] [19] However, the effect of the Fv-4 r env product against viral infection was controversial in an in vitro experimental system 20 and the immunologic protection mechanism of the Fv-4 r -bearing hosts was noted. [21] [22] [23] [24] Since the treatment of AIDS patients requires a rescue mechanism in an immunodeficient state, the receptor interference aspects of r gene function should be emphasized. To examine whether the receptor interference phenomenon actually occurred in our gene transduction system, we constructed a green fluorescence protein (GFP)-conjugated Friend MuLV derived env protein (GFP-Fr-ENV) and demonstrated competitive binding of Fr-ENV with the Fv-4 r env product to the cell surface. Then, to generate a gene therapy model for AIDS, immunocompromised hosts were prepared by thymectomy, transplanted with Fv-4 r env gene-transduced bone marrow cells, and tested for resistance against FLV-induced leukemogenesis. We could demonstrate a successful gene therapy model against retroviral infection even in an immunosuppressed state, and discussed the mechanism of the transduced Fv-4 r gene function in this model system.
Materials and methods

Construction of bone marrow chimeras
Specific pathogen-free (SPF) C3H/HeMsNrs (C3H, Fv-4 s , FLVsensitive) male mice, 8 to 12 weeks old, were pretreated with 5-fluorouracil (150 ng/kg) intraperitoneally 4 days before death. Bone marrow cells were collected and cocultured with an irradiated Ampli GPE/LSF-Fv4env packaging cell line for 48 h in ␣MEM (GIBCO-BRL, Rockville, MD, USA) supplemented with 20% FCS and a 10% conditioned medium of IL-3-producing murine T cell leukemia (8313) 25 in the presence of polybrene (4 g/ml). The retroviral vector coding Fv-4 r env gene (pLSF/Fv4env) was constructed as described earlier. 12 Bone marrow chimeras were generated as described previously. 26, 27 Briefly, bone marrow cells were harvested, washed, and 10 6 cells were injected intravenously into lethally (10.5 Gy) irradiated syngeneic C3H host mice (Fv-4 r -C3H → C3H). As a control, C3H bone marrow cells were also transplanted into irradiated C3H mice (C3H → C3H). To create bone marrow chimeras in an immunosuppressive state, thymectomy (Tx) of the host C3H mice was performed before irradiation, and then bone marrow cells were transplanted (Fv-4 r -C3H → TxC3H and C3H → TxC3H). All animals were maintained within a clean conventional animal facility in which SPF was maintained according to our criteria. 
Infection of virus
Mice were inoculated i.p. with FLV complex consisting of replication-defective spleen focus forming virus (SFFV) and replication-competent Friend MuLV. The dose inoculated was highly leukemogenic 10 4 p.f.u./mouse (10 3 times the LD 50 ) or 10 5 p.f.u./mouse. The titer of the virus was determined by the UV-XC test. 29 
Construction of GFP-Fr-ENV
The fusion gene Friend surface unit (SU)-green fluorescence protein (GFP) was derived from the SU gene of Friend MuLV clone 57 30 and the GFP gene (Clontech Laboratories, Palo Alto, CA, USA). The DNA construction procedure will be reported elsewhere in detail. 31 Briefly, a 1.5 kb XbaI-SfcI fragment (nucleotide positions 5637-7178) of the Friend SU gene, including almost the entire SU region, was blunt-ended and inserted into the SmaI site of pEGFP-1 (Clontech Laboratories) so that the GFP fused to the C-terminal of SU. The entire Friend SU-GFP fusion gene was amplified by PCR and inserted into the BamHI site of a pAcYM1 baculovirus transfer vector. 31 The recombinant transfer vector and Bsu36I-digested baculovirus DNA (AcRP23.LacZ) 33 were cotransfected into Sf21AE cells, and then a recombinant virus producing the Friend SU-GFP fusion protein was selected. Tn5 B1-4 cells were infected by the recombinant virus and 3 days after infection the serumfree culture supernatant of the infected cells was collected and used as the GFP-ENV fusion protein solution. Sf21AE and Tn5 B1-4 were insect cell lines derived from Spodoptera frugipeda or Trichoplusia ni. The GFP-Fr-ENV protein contained 97% of the Friend SU domain, including the putative mCAT-1 receptor binding region. The mCAT-1 specific binding of the GFPFr-ENV fusion protein produced in the insect cells was demonstrated by flow cytometric analysis using mCAT-1 genenegative rabbit SIRC cells and mCAT-1 gene-transfected SIRC cells. 31 
Binding assay of GFP-Fr-ENV to PBMC and spleen cells
PBMCs from Fv-4 r -C3H → C3H chimeras with various degrees of Fv-4 r env gene expression were taken from the tail vein, hemolysed with 0.83% NH 4 Cl, washed with PBS, and mixed with 100 l of GFP-Fr-ENV solution for 30 min at 4°C. After washing and centrifugation, cells were stained with a polyclonal anti GFP antibody (Clontech Laboratories) followed by FITC-conjugated anti rabbit IgG (DAKO, Carpinteria, CA, USA) and a biotin-conjugated monoclonal antibody to the Fv-4 r env product (4D2) followed by PE-conjugated streptavidin. Two-color fluorescence analysis was performed on a FACScan and the mean fluorescence intensity of each sample was evaluated. To estimate the effect of the Fv-4 r env product from outside of the cell on binding of GFP-Fr-ENV, spleen cells from C3H mice were mixed with 100 l of C4W serum (dilution ×1, ×2, ×5, ×10, ×20 and ×50) for 30 min at 4°C, centrifuged, and then mixed with 100 l of GFP-Fr-ENV for 30 min at 4°C. Staining for GFP-Fr-ENV and the Fv-4 r env product was performed as described above. As a control, C3H spleen cells mixed with C3H serum and C4W spleen cells were also mixed with GFP-Fr-ENV and analyzed.
Results
Expression of the Fv-4 r env gene after bone marrow transplantation
To study the expression of the Fv-4 r env product in Fv-4 r -C3H → C3H chimeras, the fluorescence intensity of the Fv-4 r env product on PBMCs was determined as described previously. 12 The mean fluorescence intensity of PBMCs in each Fv-4 r -C3H → C3H chimera varied from about 10% to 100% of the intensity in C4W PBMCs (Figure 1 ). The average intensity in total PBMCs of Fv-4 r -C3H → C3H chimeras was 58% of the intensity of C4W PBMCs. The expression efficiency of PBMCs was satisfactory. Further, the expression was preserved at a high level for more than 1 year. Table 1 shows the Fv-4 r expression state in the PBMC of chimera mice 18 months after gene transduction. As indicated, strong enough and long-term expression was achieved under the control of the retroviral vector system. Expression of the Fv-4 r env gene product was sufficient on PBMC from Fv-4 r -C3H → C3H chimeras (experiments 1 and 2). In both experiments, the majority of chimera mice expressed the Fv-4 r env product on the cell surface with an intensity stronger than 30% of the control intensity by PBMC from C4W mice. Lymphoid or myeloid cells were gated by forward and laser beam side scatters on a FACScan and the fluorescence intensity for Fv-4 r expression was analyzed. The mean values of intensity for lymphoid and myeloid cells were 36.8 ± 14.9% (mean ± s.d.) and 88.6 ± 42.8%, respectively in experiment 1 (n = 16) and 32.7 ± 23.8% and 69.6 ± 49.5% in experiment 2 (n = 17). more than 30% of the intensity of C4W compared using the expression in PBMCs are shown in Figure 2a and chimeras with more than 30% or 50% intensity in Figure 2b . When mice were inoculated with 10 4 p.f.u. of FLV (a), the survival time of Fv-4 r -C3H → C3H chimeras was significantly longer than that of C3H → C3H mice (P Ͻ 0.001, by generalized Wilcoxon's test). The majority of chimeras survived for more than 200 days and died with no evidence of leukemia. Thus, they were basically FLV-resistant. It was noted that some of the Fv-4 r -C3H → C3H chimeras that died within 100 days of inoculation with FLV manifested a severely anemic condition.
Effects of Fv-4 r env gene transduction on susceptibility to retrovirus-induced disease
Further, most chimeras with strong expression of the Fv-4 r env product (Ͼ50% of C4W mice) resisted FLV-induced leukemogenesis after inoculation with 10 5 p.f.u. of FLV, a dose about 10 4 times the LD 50 in C3H mice (Figure 2b ). Such a strong gene transduction effect would be satisfactory as a resistance-inducing therapy model against viral infection. However, when the survival time was observed on chimeras expressing Fv-4 r env with intensities 30% to 50% of C4W mice, the majority of mice died from FLV-induced leukemia. In (a), note that the majority of chimeras survived for longer than 200 days, when irradiated mice died from non-specific organ insufficiency. In contrast, all C3H → C3H mice died from FLV-induced leukemia within 150 days after inoculation with FLV. When higher doses of FLV were inoculated as shown in (b), some chimera mice died from FLV-induced leukemia. However, the chimera mice with higher expression of the Fv-4 r env product (more than 50% of the control) were almost refractory to FLV inoculation. amount of ENV binding was inversely correlated to the intensity of Fv-4 r gene expression on PBMCs. As expected, PBMCs from chimeras with more than 30 to 40% Fv-4 r expression of C4W PBMCs did not bind to GFP-Fr-ENV. These findings were consistent with the fact that Fv-4 r -C3H → C3H chimeras with more than 30% Fv-4 r gene expression of C4W mice were resistant to FLV-induced leukemogenesis.
Binding of GFP-Fr-ENV to cells inhibited by the
Next, we observed whether the binding of GFP-Fr-ENV to hematopoietic cells was inhibited by the Fv-4 r gene product from outside the cell. Spleen cells of C3H mice were mixed with various concentrations of C4W serum. These cells exhibited binding of the Fv-4 r env product on the cell surface in a serum-concentration dependent manner. Then the cells were mixed with GFP-Fr-ENV. The curve in Figure 3b 
Effects of thymectomy on the susceptibility of Fv-4 r env gene transduced bone marrow chimeras to retrovirus-induced disease
To test how the immunologic protection mechanism of the host may contribute to resistance against FLV-induced leukemogenesis in Fv-4 r -C3H → C3H chimeras, immunosuppressed chimeras, were generated by thymectomy (Tx) of the host mice before bone marrow transplantation. Thymectomized mice reconstituted with syngeneic bone marrow cells revealed a considerable degree of immunosuppression. 34 If the immunologic functions of the host are essential to resist FLV-induced leukemia, Fv-4 r -C3H → TxC3H chimeras would become susceptible to FLV-induced leukemogenesis to some extent. However, as shown in Figure 4 , chimeras were basically resistant to FLV-induced leukemogenesis when they expressed the Fv-4 r gene product more than 30% of C4W mice on the cell surface. These findings suggested that the receptor interference effects of the Fv-4 r env gene may work well, even in immunosuppressed hosts, when the Fv-4 r product is sufficiently expressed on the cell surface.
Discussion
One approach to gene therapy for retrovirus-induced disease is to block the entry of virions into cells by transducing an inhibitory gene that functions as a receptor blocker. 35 As for HIV infection, CD4 receptor and co-receptors for CD4 receptors, chemokine receptors, were identified 36, 37 and natural/ synthetic ligands to these receptors were demonstrated to block HIV infection. [4] [5] [6] [7] [8] [9] [10] [11] Thus, inhibition of virus-receptor binding could become a major goal of AIDS therapy. In murine model systems, a host gene that works probably via a receptor interference mechanism has been identified. [13] [14] [15] [16] This host gene, Fv-4 r , mediates strong resistance to retroviral infection. Introduction of the Fv-4 r env gene into virus-susceptible cells confers resistance against ecotropic MuLV, but not amphotropic or dualtropic MuLVs. 15 The efficiency of Fv-4 r gene transduction has been clearly shown in a study using Fv-4 r transgenic mice. 21 The present study confirmed that retrovirus-mediated gene therapy is also effective. As expected, the present study, as well as the work on transgenic mice, found that resistance is dependent on the degree of Fv-4 r gene expression.
Recently, a virus-free Fv-4 r env protein was detected in the serum of Fv-4 r -bearing mice and shown to bind to the ecotropic MuLV receptor and block infection by MuLVs. 17, 18 Thus, both intracellular 14 and extracellular effects 17, 18, 38 can be considered for the induced resistance. Extracellular effects may be very advantageous for gene therapy, because the transduced gene would not be expressed in all of the target cells. This phenomenon was indicated previously by the fact that C4W+C3H → C3H mixed bone marrow chimeras resisted FLV-induced leukemogenesis when mice had as low as 30% C4W-derived cells. 27 In the present study, the amount of One of the main impediments to effective gene therapy for hematological disorders is the resistance of hematopoietic stem cells to stable genetic modification. Using an SFFV-vector gene transduction system, we showed here that efficient and long-lasting gene expression can be realized in vivo using bone marrow transplantation. The strong expression continued for more than 1 year.
Despite the enormous beneficial effects of a highly active antiretroviral therapy for AIDS, the emergence of strains of HIV that are resistant to currently available drugs is a widespread and growing problem. 2, 39 Thus, the development of new classes of AIDS drugs is vital. One plausible target for such agents is HIV-1 entry into CD4
+ cells, as shown by clinical trials of T-20, a peptide that prevents the functioning of the viral gp41 fusion glycoprotein and stops HIV-1 from penetrating the cells. 40 However, antibody production against such agents by the host may be a problem when the agents are used frequently over long periods in vivo. Our model system could avoid this problem in the sense that antibodies against transduced gene products would not be produced, since immune tolerance is induced against newly introduced antigens after bone marrow transplantation. 41, 42 This method would also have the benefit that the expected effects of gene products would be continuous and last for a long time. Thus, the present study could provide an animal model of env-associated gene transduction as a useful therapy tool in retrovirusinduced immunodeficient diseases.
In conclusion, we generated a gene therapy model for retrovirus-induced disease by transduction of a truncated viral env gene, the Fv-4 r gene, into the bone marrow cells of Fv-4 r -sensitive mice followed by bone marrow transplantation to a syngeneic host in an immunosuppresive state. The bone marrow chimera mice with the Fv-4 r -transduced hematopoietic cells resisted FLV-induced leukemogenesis in an expression intensity-dependent manner.
